Table 1.
Characteristics of The Framingham Heart Study Offspring Cohort Participants Included in Analyses for Deriving the Trajectory Patterns (maximum n = 3,453) or in the Cross-sectional and Outcome Analyses (maximum n = 2,748)
| Characteristics of the Trajectory Derivation Sample at in 1991–1995 | Characteristics of the Cross-sectional and Outcome Analysis Sample at in 2005–2008 | |||||||
|---|---|---|---|---|---|---|---|---|
| Women | Men | Women | Men | |||||
| Characteristic | n | Measure | n | Measure | n | Measure | n | Measure |
| Age, y | 1,852 | 54.6 (9.3) | 1,601 | 54.9 (9.2) | 1,516 | 67.2 (8.9) | 1,232 | 67.1 (8.6) |
| BMD, g/cm2 | 1,578* | 0.91 (0.15) | 1,243 | 1.04 (0.15) | 925 | 0.90 (0.13) | 792 | 1.0 (0.2) |
| BMI, kg/m2 | 1,837 | 26.8 (5.5) | 1,596 | 28.2 (4.1) | 1,457 | 27.7 (5.8) | 1,202 | 29.0 (4.7) |
| CRP, mg/dL, median (IQR) | 1,786 | 1.7 (0.3, 5.6) | 1,568 | 1.5 (0.4, 4.3) | 1,443 | 1.6 (0.8, 3.5) | 1,199 | 1.5 (0.8, 2.9) |
| eGFR, mL/min/1.73 m2 | 1,542 | 89.1 (19.4) | 1,353 | 88.9 (18.7) | 1,442 | 77.3 (16.4) | 1,199 | 77.7 (16.5) |
| FEV1/FVC, % | 1,593 | 0.74 (0.07) | 1,383 | 0.73 (0.07) | 1,308 | 0.73 (0.07) | 1,052 | 0.71 (0.08) |
| FVC, mL | 1,593 | 3313 (595) | 1,383 | 4611 (833) | 1,308 | 3037 (590) | 1,052 | 4341 (904) |
| Gait time, s | 1,222† | 3.4 (1.1) | 1,059 | 3.3 (0.7) | 1,452 | 3.6 (1.0) | 1,192 | 3.5 (0.9) |
| Grip strength, kg | 1,116† | 24.3 (7.6) | 966 | 42.9 (10.1) | 1,474 | 23.3 (6.0) | 1,212 | 40.5 (9.7) |
| Hba1c, % | 1,328 | 5.4 (0.9) | 1,126 | 5.5 (1.1) | 1,449 | 5.7 (0.6) | 1,203 | 5.7 (0.7) |
| Heart rate, 1/min | 1,852 | 67.3 (10.7) | 1,601 | 63.2 (11.3) | 1,516 | 63.9 (10.2) | 1,231 | 60.8 (10.9) |
| LVMI, g/m2 | 1,492 | 86.8 (18.6) | 1,132 | 103.9 (20.7) | 1,227 | 86.6 (18.4) | 900 | 103.6 (19.9) |
| MMSE, points | 1,845 | 29.1 (1.3) | 1,593 | 28.6 (1.6) | 1,505 | 28.6 (2.5) | 1,221 | 28.2 (2.1) |
| Pulse pressure, mmHg | 1,852 | 51.7 (16.1) | 1,601 | 52.6 (14.0) | 1,514 | 58.7 (17.6) | 1,231 | 57.3 (16.1) |
| TC/HDL ratio | 1,829 | 4.0 (1.4) | 1,590 | 5.0 (1.5) | 1,449 | 3.3 (0.9) | 1,202 | 3.7 (1.1) |
| BP medication, No. (%) | 1,844 | 315 (17.1) | 1,595 | 312 (19.6) | 1,515 | 706 (46.6) | 1,230 | 674 (54.8) |
| Lipid medication, No. (%) | 1,852 | 105 (5.7) | 1,600 | 143 (8.9) | 1,515 | 578 (38.2) | 1,230 | 615 (50.0) |
| Diabetes medication, No. (%) | 1,851 | 51 (2.8) | 1,601 | 62 (3.9) | 1,466 | 117 (8.0) | 1,159 | 142 (12.3) |
Note: BMD = Bone mineral density; BMI = Body mass index: CRP = C-reactive protein; eGFR = Estimated glomerular filtration rate; FEV1 = 1 Second forced expiratory volume; FVC = Forced vital capacity; HbA1c = Glycated hemoglobin; HDL = High-density lipoprotein cholesterol; LVMI = Left ventricular mass index; MMSE = Mini-Mental State Examination; TC = Total cholesterol. *Presenting examination was six instead of five. †Presenting examination was seven instead of five.